Strattera (atomoxetine hydrochloride) is a non-stimulant medication approved to treat the symptoms of attention deficit hyperactivity disorder, or ADHD, in children and adults. This medication works to alleviate symptoms of inattention, hyperactivity, and impulsivity. One benefit over the often-prescribed stimulant medications is that Strattera does not have the same risk of abuse that stimulants do.
How It Works
Strattera is a selective norepinephrine reuptake inhibitor and works to increase available levels of norepinephrine in the brain. Unlike stimulants, which begin working immediately, Strattera takes a few weeks to reach therapeutic levels in the body. According to the National Resource Center on ADHD, it appears to be effective in treating ADHD symptoms.
Forms
Strattera is prescribed in capsule form for individuals with ADHD. The National Resource Center on ADHD indicates that most individuals take the medication once or twice a day to manage symptoms over a 24-hour period. Physicians often begin individuals at a low dose and gradually increase the dosage.
Common Side Effects
There are some side effects commonly accompany Straterra. Side effects in children and teens may include dizzy spells, sleepiness, nausea, stomachache, little appetite and changes in mood. In adults, side effects may include nausea, dry mouth, insomnia, constipation, and decrease in appetite.
Serious Side Effects
The U.S. Food and Drug Administration describes other more serious side effects of Strattera, which include risk of liver damage, heart problems, high blood pressure, and psychotic problems such as paranoia and auditory hallucinations. Additional side effects may include slowed growth in children, allergic reactions to the medication, and urinary problems.
Risk of Suicidal Thoughts
The U.S. Food and Drug Administration reports that children and adolescents who take Strattera are at greater risk of having thoughts of suicide. This is a rare side effect, but was found to occur in four in every 1,000 individuals. This risk is higher when children or adolescents have their dosage changed and in the early stages of treatment. Due to the risk of thoughts leading to behavior, it is important to monitor children’s behavior to look for warning signs.
